临床生物标志物在过敏喘诊断和严重性的相互作用:一个病例对照研究
Zainab Khaleel Mohammed1, Shukur Wasman Smail2, Christer Janson3
1Department of Microbiology, College of Medicine, University of Sulaimani, Sulaimaniyah, Iraq. zainab.mohammed@univsul.edu.iq.
概括
这项研究发现,与健康对照组相比,过敏性喘 (AA) 患者的特定血液和血清生物标志物水平升高. 这些生物标志物,包括IgE和MMP-16,与肺功能减弱相关,表明它们的诊断和监测潜力.
科学领域:
- 免疫学 免疫学 免疫学
- 肺部病理学 肺部病理学
- 生物化学 生物化学
背景情况:
- 过敏性喘 (AA) 呈现出显著的表型多样性.
- 准确的特征和AA的严重程度评估对于有效的管理至关重要.
- 现有的诊断方法可能会从纳入新生物标志物中受益.
研究的目的:
- 识别和描述过敏性喘 (AA) 的特定血液和血清生物标志物.
- 评估这些生物标志物与AA患者的肺功能参数之间的相关性.
- 评估这些生物标志物在诊断和监测AA.的潜在用处.
主要方法:
- 从96名AA患者和42名健康对照 (HC) 收集了血液样本.
- 测量包括血液学参数 (例如白细胞计数),血清生物标志物 (例如IgE,ECP,MMP-9,FGF-18) 和肺功能测试 (FEV1,FVC).
- 进行了统计分析,以比较群体之间的生物标志物水平,并评估相关性.
主要成果:
- 与HC相比,AA患者的总白细胞,乙氨基基,基氨基,IgE,三酶,ECP,MMP-9,MMP-16,FGF-18,FGF-23和ACTa-1水平显著更高.
- 强迫呼气体积1 (FEV1) 和强迫生命能力 (FVC) 与ECP,IgE,ACTa-1和MMP-16有负相关性.
- 在AA患者中观察到MMP-9,MMP-16,FGF-18,FGF-23,IgE,酶和ACTa-1的水平升高.
结论:
- 在过敏性喘患者中,特定的血液和血清生物标志物升高.
- 一些生物标志物,包括IgE,酶,ACTa-1和MMP-16,在AA中与肺功能障碍有关.
- 测量一组生物标志物可以提高过敏喘的诊断和监测.
相关概念视频
Asthma-IV: Diagnostic and Management
2.5K
The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
2.5K
Asthma-II: Pathophysiology and Classification
2.6K
Asthma is a prevalent chronic respiratory condition marked by inflammation and hyperresponsiveness of the airways. Its pathophysiology involves complex interactions among inflammatory pathways, immune responses, and neural mechanisms.
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
2.6K
Asthma: Pathogenesis and Management
386
Asthma is a chronic pulmonary condition involving inflammation of the airways, hyper-reactivity, and reversible obstruction of the airways. This condition can significantly impact a person's quality of life, making breathing difficult and leading to distressing symptoms.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
386
Asthma-I: Introduction
2.6K
Asthma is a chronic respiratory ailment that requires careful management due to its varying symptoms and influencing factors. It is characterized by airway inflammation, bronchial hyperresponsiveness, and reversible airflow obstruction, leading to symptoms like wheezing, shortness of breath, chest tightness, and coughing. The symptom frequency and intensity may vary considerably over time. It is also linked to immune system responses to allergens and irritants, highlighting the complex...
2.6K
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
271
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
271
Asthma-III: Symptoms and Complications
2.5K
Asthma, a common chronic respiratory condition, is classified considering the frequency and severity of symptoms alongside lung function impairment. Understanding this classification is essential for appropriate treatment and management. Here's a detailed look at the classification of asthma and its clinical features and complications:
Classification of Asthma
Classification of Asthma
2.5K


